Abstracts tagged "Adalimumab and inflammatory bowel disease (IBD)"

Abstract Number: 1931 • 2012 ACR/ARHP Annual Meeting
Influence of Trough Serum Drug Level and Immunogenicity On the Lack of Response to Adalimumab Therapy in Inflammatory Bowel Disease Patients
Shui Long Wang¹, Scott Hauenstein¹, Linda Ohrmund¹, Reshma Shringarpure², Douglas C. Wolf³, Isam A. Diab⁴, Jared Salbato¹, Rukmini Reddy¹, Kevin McCowen¹, Shawn Shah¹, Steven Lockton¹, Emil Chuang² and Sharat Singh¹, ¹Research and Development, Prometheus Laboratories, San Diego, CA, ²Clinical and Medical Affairs, Prometheus Laboratories, San Diego, CA, ³Atlanta Gastroenterology Associates, Atlanta, GA, ⁴Paramount Medical Research & Consulting, Middleburg Heights, OH
Background/Purpose: Anti-TNF-α therapy is effective for the treatment of inflammatory bowel disease (IBD). Nevertheless, over 30% of IBD patients fail to respond to anti-TNF-α therapy…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Abstracts tagged "Adalimumab and inflammatory bowel disease (IBD)"

Influence of Trough Serum Drug Level and Immunogenicity On the Lack of Response to Adalimumab Therapy in Inflammatory Bowel Disease Patients